Shutaishen (300204.SZ) shareholder Xiangtang Group has reduced its holdings by about 5% Post date May 14, 2022 — 12:00 Post Lock Read More Shu Taishen: The company's production and operation activities are normal_Finance Bei EHZ / Financial Diamond Value Drive Post date May 14, 2022 — 11:28 Post Lock Read More Financial Associated Press May 9 Morning Post (Monday) Post date May 9, 2022 — 07:40 Post Lock Read More Financial Associated Press May 9 Morning Post (Monday) New Crown in Yuhua District, Urbanization Industrial Park jqknews Post date May 9, 2022 — 07:40 Post Lock Read More Observation: The first results of the industrial integration layout are seen, and Saito Bio is worthy of attention Post date May 6, 2022 — 20:48 Post Lock Read More In 2021, A-share R&D expenses will exceed 1,200 billion yuan, and pharmaceutical and biological companies are "most invested"_Shenzhen Hotline Post date May 6, 2022 — 11:48 Post Lock Read More In 2021, A-share R&D expenses will exceed 1.2 trillion yuan, and pharmaceutical and biological companies are "most invested" Post date May 6, 2022 — 06:50 Post Lock Read More Shu Taishen: We hold global rights to STSP-0601 Post date April 29, 2022 — 00:10 Post Lock Read More Shutai Shenchuang has made the biggest loss since its listing. Can the new crown intensive treatment drug become a revenue-generating "dark horse"? ｜Hexun exposed financial report and financial channel Rongyi Information Network Post date April 22, 2022 — 02:16 Post Lock Read More Shu Taishen: 300204 Shu Taishen Research Minutes 20220420- CFi.CN Zhongcai Network Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: 300204 Shu Taishen Investor Relations Activity Record Form 20220420- CFi.CN Zhongcai.com Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: BDB-001, STSA-1002, STSA-1005 projects are in progress Post date April 20, 2022 — 18:16 Post Lock Read More Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money" Post date April 20, 2022 — 15:30 Post Lock Read More Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Shu Taishen: The company's production and operation activities are normal_Finance Bei EHZ / Financial Diamond Value Drive Post date May 14, 2022 — 11:28 Post Lock Read More Financial Associated Press May 9 Morning Post (Monday) Post date May 9, 2022 — 07:40 Post Lock Read More Financial Associated Press May 9 Morning Post (Monday) New Crown in Yuhua District, Urbanization Industrial Park jqknews Post date May 9, 2022 — 07:40 Post Lock Read More Observation: The first results of the industrial integration layout are seen, and Saito Bio is worthy of attention Post date May 6, 2022 — 20:48 Post Lock Read More In 2021, A-share R&D expenses will exceed 1,200 billion yuan, and pharmaceutical and biological companies are "most invested"_Shenzhen Hotline Post date May 6, 2022 — 11:48 Post Lock Read More In 2021, A-share R&D expenses will exceed 1.2 trillion yuan, and pharmaceutical and biological companies are "most invested" Post date May 6, 2022 — 06:50 Post Lock Read More Shu Taishen: We hold global rights to STSP-0601 Post date April 29, 2022 — 00:10 Post Lock Read More Shutai Shenchuang has made the biggest loss since its listing. Can the new crown intensive treatment drug become a revenue-generating "dark horse"? ｜Hexun exposed financial report and financial channel Rongyi Information Network Post date April 22, 2022 — 02:16 Post Lock Read More Shu Taishen: 300204 Shu Taishen Research Minutes 20220420- CFi.CN Zhongcai Network Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: 300204 Shu Taishen Investor Relations Activity Record Form 20220420- CFi.CN Zhongcai.com Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: BDB-001, STSA-1002, STSA-1005 projects are in progress Post date April 20, 2022 — 18:16 Post Lock Read More Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money" Post date April 20, 2022 — 15:30 Post Lock Read More Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Financial Associated Press May 9 Morning Post (Monday) Post date May 9, 2022 — 07:40 Post Lock Read More Financial Associated Press May 9 Morning Post (Monday) New Crown in Yuhua District, Urbanization Industrial Park jqknews Post date May 9, 2022 — 07:40 Post Lock Read More Observation: The first results of the industrial integration layout are seen, and Saito Bio is worthy of attention Post date May 6, 2022 — 20:48 Post Lock Read More In 2021, A-share R&D expenses will exceed 1,200 billion yuan, and pharmaceutical and biological companies are "most invested"_Shenzhen Hotline Post date May 6, 2022 — 11:48 Post Lock Read More In 2021, A-share R&D expenses will exceed 1.2 trillion yuan, and pharmaceutical and biological companies are "most invested" Post date May 6, 2022 — 06:50 Post Lock Read More Shu Taishen: We hold global rights to STSP-0601 Post date April 29, 2022 — 00:10 Post Lock Read More Shutai Shenchuang has made the biggest loss since its listing. Can the new crown intensive treatment drug become a revenue-generating "dark horse"? ｜Hexun exposed financial report and financial channel Rongyi Information Network Post date April 22, 2022 — 02:16 Post Lock Read More Shu Taishen: 300204 Shu Taishen Research Minutes 20220420- CFi.CN Zhongcai Network Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: 300204 Shu Taishen Investor Relations Activity Record Form 20220420- CFi.CN Zhongcai.com Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: BDB-001, STSA-1002, STSA-1005 projects are in progress Post date April 20, 2022 — 18:16 Post Lock Read More Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money" Post date April 20, 2022 — 15:30 Post Lock Read More Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Financial Associated Press May 9 Morning Post (Monday) New Crown in Yuhua District, Urbanization Industrial Park jqknews Post date May 9, 2022 — 07:40 Post Lock Read More Observation: The first results of the industrial integration layout are seen, and Saito Bio is worthy of attention Post date May 6, 2022 — 20:48 Post Lock Read More In 2021, A-share R&D expenses will exceed 1,200 billion yuan, and pharmaceutical and biological companies are "most invested"_Shenzhen Hotline Post date May 6, 2022 — 11:48 Post Lock Read More In 2021, A-share R&D expenses will exceed 1.2 trillion yuan, and pharmaceutical and biological companies are "most invested" Post date May 6, 2022 — 06:50 Post Lock Read More Shu Taishen: We hold global rights to STSP-0601 Post date April 29, 2022 — 00:10 Post Lock Read More Shutai Shenchuang has made the biggest loss since its listing. Can the new crown intensive treatment drug become a revenue-generating "dark horse"? ｜Hexun exposed financial report and financial channel Rongyi Information Network Post date April 22, 2022 — 02:16 Post Lock Read More Shu Taishen: 300204 Shu Taishen Research Minutes 20220420- CFi.CN Zhongcai Network Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: 300204 Shu Taishen Investor Relations Activity Record Form 20220420- CFi.CN Zhongcai.com Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: BDB-001, STSA-1002, STSA-1005 projects are in progress Post date April 20, 2022 — 18:16 Post Lock Read More Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money" Post date April 20, 2022 — 15:30 Post Lock Read More Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Observation: The first results of the industrial integration layout are seen, and Saito Bio is worthy of attention Post date May 6, 2022 — 20:48 Post Lock Read More In 2021, A-share R&D expenses will exceed 1,200 billion yuan, and pharmaceutical and biological companies are "most invested"_Shenzhen Hotline Post date May 6, 2022 — 11:48 Post Lock Read More In 2021, A-share R&D expenses will exceed 1.2 trillion yuan, and pharmaceutical and biological companies are "most invested" Post date May 6, 2022 — 06:50 Post Lock Read More Shu Taishen: We hold global rights to STSP-0601 Post date April 29, 2022 — 00:10 Post Lock Read More Shutai Shenchuang has made the biggest loss since its listing. Can the new crown intensive treatment drug become a revenue-generating "dark horse"? ｜Hexun exposed financial report and financial channel Rongyi Information Network Post date April 22, 2022 — 02:16 Post Lock Read More Shu Taishen: 300204 Shu Taishen Research Minutes 20220420- CFi.CN Zhongcai Network Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: 300204 Shu Taishen Investor Relations Activity Record Form 20220420- CFi.CN Zhongcai.com Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: BDB-001, STSA-1002, STSA-1005 projects are in progress Post date April 20, 2022 — 18:16 Post Lock Read More Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money" Post date April 20, 2022 — 15:30 Post Lock Read More Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
In 2021, A-share R&D expenses will exceed 1,200 billion yuan, and pharmaceutical and biological companies are "most invested"_Shenzhen Hotline Post date May 6, 2022 — 11:48 Post Lock Read More In 2021, A-share R&D expenses will exceed 1.2 trillion yuan, and pharmaceutical and biological companies are "most invested" Post date May 6, 2022 — 06:50 Post Lock Read More Shu Taishen: We hold global rights to STSP-0601 Post date April 29, 2022 — 00:10 Post Lock Read More Shutai Shenchuang has made the biggest loss since its listing. Can the new crown intensive treatment drug become a revenue-generating "dark horse"? ｜Hexun exposed financial report and financial channel Rongyi Information Network Post date April 22, 2022 — 02:16 Post Lock Read More Shu Taishen: 300204 Shu Taishen Research Minutes 20220420- CFi.CN Zhongcai Network Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: 300204 Shu Taishen Investor Relations Activity Record Form 20220420- CFi.CN Zhongcai.com Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: BDB-001, STSA-1002, STSA-1005 projects are in progress Post date April 20, 2022 — 18:16 Post Lock Read More Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money" Post date April 20, 2022 — 15:30 Post Lock Read More Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
In 2021, A-share R&D expenses will exceed 1.2 trillion yuan, and pharmaceutical and biological companies are "most invested" Post date May 6, 2022 — 06:50 Post Lock Read More Shu Taishen: We hold global rights to STSP-0601 Post date April 29, 2022 — 00:10 Post Lock Read More Shutai Shenchuang has made the biggest loss since its listing. Can the new crown intensive treatment drug become a revenue-generating "dark horse"? ｜Hexun exposed financial report and financial channel Rongyi Information Network Post date April 22, 2022 — 02:16 Post Lock Read More Shu Taishen: 300204 Shu Taishen Research Minutes 20220420- CFi.CN Zhongcai Network Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: 300204 Shu Taishen Investor Relations Activity Record Form 20220420- CFi.CN Zhongcai.com Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: BDB-001, STSA-1002, STSA-1005 projects are in progress Post date April 20, 2022 — 18:16 Post Lock Read More Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money" Post date April 20, 2022 — 15:30 Post Lock Read More Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Shu Taishen: We hold global rights to STSP-0601 Post date April 29, 2022 — 00:10 Post Lock Read More Shutai Shenchuang has made the biggest loss since its listing. Can the new crown intensive treatment drug become a revenue-generating "dark horse"? ｜Hexun exposed financial report and financial channel Rongyi Information Network Post date April 22, 2022 — 02:16 Post Lock Read More Shu Taishen: 300204 Shu Taishen Research Minutes 20220420- CFi.CN Zhongcai Network Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: 300204 Shu Taishen Investor Relations Activity Record Form 20220420- CFi.CN Zhongcai.com Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: BDB-001, STSA-1002, STSA-1005 projects are in progress Post date April 20, 2022 — 18:16 Post Lock Read More Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money" Post date April 20, 2022 — 15:30 Post Lock Read More Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Shutai Shenchuang has made the biggest loss since its listing. Can the new crown intensive treatment drug become a revenue-generating "dark horse"? ｜Hexun exposed financial report and financial channel Rongyi Information Network Post date April 22, 2022 — 02:16 Post Lock Read More Shu Taishen: 300204 Shu Taishen Research Minutes 20220420- CFi.CN Zhongcai Network Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: 300204 Shu Taishen Investor Relations Activity Record Form 20220420- CFi.CN Zhongcai.com Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: BDB-001, STSA-1002, STSA-1005 projects are in progress Post date April 20, 2022 — 18:16 Post Lock Read More Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money" Post date April 20, 2022 — 15:30 Post Lock Read More Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Shu Taishen: 300204 Shu Taishen Research Minutes 20220420- CFi.CN Zhongcai Network Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: 300204 Shu Taishen Investor Relations Activity Record Form 20220420- CFi.CN Zhongcai.com Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: BDB-001, STSA-1002, STSA-1005 projects are in progress Post date April 20, 2022 — 18:16 Post Lock Read More Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money" Post date April 20, 2022 — 15:30 Post Lock Read More Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Shu Taishen: 300204 Shu Taishen Investor Relations Activity Record Form 20220420- CFi.CN Zhongcai.com Post date April 20, 2022 — 22:27 Post Lock Read More Shu Taishen: BDB-001, STSA-1002, STSA-1005 projects are in progress Post date April 20, 2022 — 18:16 Post Lock Read More Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money" Post date April 20, 2022 — 15:30 Post Lock Read More Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Shu Taishen: BDB-001, STSA-1002, STSA-1005 projects are in progress Post date April 20, 2022 — 18:16 Post Lock Read More Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money" Post date April 20, 2022 — 15:30 Post Lock Read More Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money" Post date April 20, 2022 — 15:30 Post Lock Read More Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network Post date April 20, 2022 — 11:49 Post Lock Read More The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7% Post date April 19, 2022 — 15:30 Post Lock Read More Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon. Post date April 19, 2022 — 15:29 Post Lock Read More [News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
[News] Shu Taishen Announces Annual Report CFi.CN Post date April 19, 2022 — 01:31 Post Lock Read More Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%. Post date April 19, 2022 — 00:31 Post Lock Read More Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online Post date April 19, 2022 — 00:07 Post Lock Read More Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Integrate and optimize resources Shutaishen plans to absorb and merge Defengrui Post date April 18, 2022 — 22:38 Post Lock Read More
Caishen.CoCaishen.Co